The Quantellect read.As of Nov 19, 2026, 4 active firms cover ICU Medical Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $182.00 to $200.00, so the covering firms are broadly aligned. The average target of $191.00 sits 7% above the current $178.50. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.13 next quarter toward $9.68 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$191.00
+7.0% upside
Average target across 4 active firms as of Nov 19, 2026 vs $178.50 current
Highest Target$200.00
Average Target$191.00
Lowest Target$182.00
Detailed analyst forecasts for ICUI
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate ICUI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ICUI EPS & revenue forecast
EPS · NEXT QUARTER
$2.13
Range $2.10 – $2.16 · 4 analysts · +8% YoY
Next period, 4 analysts expect ICU Medical Inc to earn $2.13 a share (range $2.10 – $2.16), versus $1.97 a year earlier. Full-year consensus is $8.93, growing to $9.68 the year after.
REVENUE · NEXT QUARTER
$545.5M
Range $543.3M – $548.4M · 4 analysts · +4% YoY
Revenue is expected to reach $545.5M (range $543.3M – $548.4M), +3.8% year-over-year. Full-year consensus is $2.2B, rising to $2.3B next year.
Top analysts covering ICU Medical Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ICUI.
#1
JB
Jayson Bedford
Raymond James · Rank #191
Buy
$180.00+0.8% to target
Overall win rate
44%
+ Follow
#2
Mike Matson
Needham · Rank #285
Buy
$187.00+4.8% to target
Overall win rate
36%
+ Follow
#3
Jason Bednar
Piper Sandler · Rank #360
Buy
$195.00+9.2% to target
Overall win rate
33%
+ Follow
#4
Tim Rezvan
Keybanc · Rank #443
Buy
$191.00+7.0% to target
Overall win rate
31%
+ Follow
#5
Brett Fishbin
KeyBanc
Buy
$182.00+2.0% to target
Coverage
—
+ Follow
ICUI stock forecast FAQ
What is ICUI's average 12-month price target?+
The 4 active firms with a live target average $191.00 for ICU Medical Inc over the next 12 months, ranging from a $200.00 high to a $182.00 low, as of Nov 19, 2026.
Is ICUI stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ICUI?+
The Street-high target is $200.00 (BTIG), and the Street-low is $182.00 (Keybanc). The average of all 4 active-firm targets is $191.00.
How many active Wall Street firms cover ICUI?+
4 active firms have a recognized rating on ICU Medical Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ICUI?+
Among analysts who currently cover ICUI, Jayson Bedford of Raymond James has the strongest overall Quantellect track record (Rank #191). Their current call is Buy with a $180.00 target.
What is ICU Medical Inc's projected EPS for next quarter?+
The consensus estimate is $2.13 per share (range $2.10 – $2.16) across 4 analysts. Full-year EPS is projected at $8.93, rising to $9.68 the following year.
How much revenue is ICU Medical Inc expected to report next quarter?+
Consensus revenue is $545.5M (range $543.3M – $548.4M). Full-year revenue is projected at $2.2B, growing to $2.3B next year.
Have analysts been upgrading or downgrading ICUI lately?+
As of Nov 19, 2026, 4 of 4 active firms rate ICUI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ICUI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.